Literature DB >> 15170826

Navigator gating and volume tracking for double-triggered cardiac proton spectroscopy at 3 Tesla.

Michael Schär1, Sebastian Kozerke, Peter Boesiger.   

Abstract

Respiratory motion compensation based on navigator echoes for double-triggered cardiac proton spectroscopy at 3.0 T is presented. The navigators measure the displacement of the liver-lung interface during free breathing. This information allows for double triggering on a defined window within the respiratory cycle and on a defined trigger delay after the R-wave based on the ECG. Furthermore, it allows the excitation volume to be shifted by the determined respiratory displacement within the defined window in real-time (volume tracking). Static and motion phantom experiments were performed in this study, and it was demonstrated that volume tracking permits the suppression of signal from tissue next to the localized volume. However, triggering on a defined respiratory position is still necessary to achieve high spectral quality, because shimming and water suppression calibration are only optimal for a small window of the respiratory cycle. Single-volume spectra obtained in the myocardial septum of healthy subjects are presented. Copyright 2004 Wiley-Liss, Inc.

Mesh:

Year:  2004        PMID: 15170826     DOI: 10.1002/mrm.20123

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  14 in total

1.  On restoring motion-induced signal loss in single-voxel magnetic resonance spectra.

Authors:  Refaat E Gabr; Shashank Sathyanarayana; Michael Schär; Robert G Weiss; Paul A Bottomley
Journal:  Magn Reson Med       Date:  2006-10       Impact factor: 4.668

2.  Limits of a localized magnetic resonance spectroscopy assay for ex vivo myocardial triacylglycerol.

Authors:  Robert D O'Connor; Robert J Gropler; Linda Peterson; Jean Schaffer; Joseph J H Ackerman
Journal:  J Pharm Biomed Anal       Date:  2007-09-01       Impact factor: 3.935

Review 3.  Quantitative proton MR techniques for measuring fat.

Authors:  H H Hu; H E Kan
Journal:  NMR Biomed       Date:  2013-10-03       Impact factor: 4.044

4.  Clinical applications for cardiovascular magnetic resonance imaging at 3 tesla.

Authors:  Allison G Hays; Michael Schär; Sebastian Kelle
Journal:  Curr Cardiol Rev       Date:  2009-08

5.  Simultaneous B(0)- and B(1)+-map acquisition for fast localized shim, frequency, and RF power determination in the heart at 3 T.

Authors:  Michael Schär; Evert-Jan Vonken; Matthias Stuber
Journal:  Magn Reson Med       Date:  2010-02       Impact factor: 4.668

6.  Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla.

Authors:  Belen Rial; Matthew D Robson; Stefan Neubauer; Jürgen E Schneider
Journal:  Magn Reson Med       Date:  2011-06-30       Impact factor: 4.668

7.  Metabolic imaging of human kidney triglyceride content: reproducibility of proton magnetic resonance spectroscopy.

Authors:  Sebastiaan Hammer; Aiko P J de Vries; Paul de Heer; Maurice B Bizino; Ron Wolterbeek; Ton J Rabelink; Joost Doornbos; Hildo J Lamb
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

Review 8.  (1)H-MR spectroscopy for analysis of cardiac lipid and creatine metabolism.

Authors:  Kiterie M E Faller; Craig A Lygate; Stefan Neubauer; Jürgen E Schneider
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

9.  Motion correction methods for MRS: experts' consensus recommendations.

Authors:  Ovidiu C Andronesi; Pallab K Bhattacharyya; Wolfgang Bogner; In-Young Choi; Aaron T Hess; Phil Lee; Ernesta M Meintjes; M Dylan Tisdall; Maxim Zaitzev; André van der Kouwe
Journal:  NMR Biomed       Date:  2020-07-20       Impact factor: 4.044

10.  High spatial resolution and temporally resolved T2* mapping of normal human myocardium at 7.0 Tesla: an ultrahigh field magnetic resonance feasibility study.

Authors:  Fabian Hezel; Christof Thalhammer; Sonia Waiczies; Jeanette Schulz-Menger; Thoralf Niendorf
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.